- Company
- Hanmi’s diabetes pipeline still standing in the storm
- by Chon, Seung-Hyun Dec 11, 2019 06:47am
- Hanmi Pharmaceutical’s efpeglenatide with the title of the biggest license-out deal to date is going through harsh times before reaching the finish line. The company’s unbent commitment for the pipeline kept it alive, despite amending the license out agreement twice and the partner company shifting R&D pipeline focus. Although it seems to have
- Opinion
- [Reporter's view] Illegal Rebate CSO
- by Lee, Jeong-Hwan Dec 11, 2019 06:40am
- I suddenly thought that the trifoliate orange is innocent when I was covering the law revision extending medical and pharmacological expenditure reports to pharmaceutical CSOs. Pharmaceutical industry ethics management (CP) experts refer to CSOs based on drug expertise as tangerines, the CSO which was altered as an illegal rebate, as trifo
- Company
- MSD’s new labor union in talks for unpaid wage compensation
- by Kim, Jin-Gu Dec 11, 2019 06:39am
- MSD Korea employees have gathered again under a new umbrella. Majority of the members previously affiliated under Korea Democratic Pharmaceutical Union MSD Chapter left and established a new labor union of their own. ‘MSD Korea Laborers’ Union’ is the new name for the independent corporate labor union. On Dec. 5, the union convened i
- Opinion
- [FOCUS]Post-evaluation necessity & task for reimbursed drugs
- by Kim, Jung-Ju Dec 11, 2019 06:39am
- As the health insurance coverage is strengthened as social insurance, value judgment becomes a very important policy task for the efficiency of payment and payment. Among them, the weight of medicines has changed along with the coverage. In the past, under the negative list system, the value of drug insurance was focused on listing more dr
- Policy
- Kolon wins approval on inhaled schizophrenia treatment
- by Lee, Tak-Sun Dec 11, 2019 06:38am
- An orally inhaled medicine for treating agitation associated with schizophrenia is to be released in Korean market for the first time. The public’s interest is heightened by the news as inhalation powder has higher speed of body absorption and delivers effect in the shortest time. , Korean Ministry of Food and Drug Safety (MFDS) on Dec.
- Company
- Korean biosimilars carving out Herceptin market share
- by Chon, Seung-Hyun Dec 10, 2019 06:31am
- Korean-made biosimilars are gaining more market share in the anticancer treatment Herceptin (trastuzumab) market. The biosimilars have now taken over more than 25 percent of the market share. The total market size has recovered the previous level, before the original’s price fell with new launches of inexpensive biosimilars. Alhtough Celltrion
- Product
- Metformin impurity amount, theoretically 1/90 of Ranitidine
- by Kim, Jin-Gu Dec 10, 2019 06:31am
- With Metformin, issues of impurity detection have been raised, and it is possible that N-nitrosodimethylamine (NDMA) will be detected much less than earlier Ranitidine or Nizatidine. According to officials at the MFDS on Dec 9, a qualitative structure activity relationship (QSAR) is used as a simple test to determine the toxicity of a su
- Company
- Metformin Self Test, undetected cases also listed
- by Lee, Tak-Sun Dec 10, 2019 06:31am
- The domestic pharmaceutical industry is responding quickly to the issue of Metformin impurities. In some cases, the MFDS has already completed testing, instructing its own testing of raw materials and finished products that may generate impurities. The rest of the companies are considering pushing the test through their own research insti
- Company
- MedPacto: “license out co-developed vactosertib in 2021”
- by Lee, Seok-Jun Dec 10, 2019 06:30am
- MedPacto predicts to sign license out deals on its star pipeline vactosertib in around 2021. Particularly, the company anticipates the license out deal would highly likely to be for the indications on colorectal, stomach and non-small cell lung cancers that are currently in co-development with MSD and AstraZeneca. Vactosertib (TEW-719
- Company
- Samil to release FDA-approved conjunctivitis treatment
- by Lee, Seok-Jun Dec 10, 2019 06:30am
- On Dec. 6, Samil Pharm announced it signed a manufacturing and commercialization license with a France-based ophthalmic R&D company, Nicox S.A. for the exclusiv rights of allergic conjunctivitis treatment Zerviate (cetirizine) in Korea. By closing the deal, Samil Pharm would receive the exclusive rights to manufacture and commercialize th
